DK0559632T3 - Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor - Google Patents

Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor

Info

Publication number
DK0559632T3
DK0559632T3 DK93870037T DK93870037T DK0559632T3 DK 0559632 T3 DK0559632 T3 DK 0559632T3 DK 93870037 T DK93870037 T DK 93870037T DK 93870037 T DK93870037 T DK 93870037T DK 0559632 T3 DK0559632 T3 DK 0559632T3
Authority
DK
Denmark
Prior art keywords
tfpi
purifying
exchange chromatography
sulfonate
refolding
Prior art date
Application number
DK93870037T
Other languages
Danish (da)
English (en)
Inventor
Judith Arlene Diaz-Collier
Mark Edward Gustafson
Tze-Chein Wun
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DK0559632T3 publication Critical patent/DK0559632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93870037T 1992-03-02 1993-03-01 Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor DK0559632T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/844,297 US5212091A (en) 1992-03-02 1992-03-02 Method of producing tissue factor pathway inhibitor

Publications (1)

Publication Number Publication Date
DK0559632T3 true DK0559632T3 (da) 1998-10-26

Family

ID=25292320

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93870037T DK0559632T3 (da) 1992-03-02 1993-03-01 Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor

Country Status (7)

Country Link
US (1) US5212091A (enExample)
EP (1) EP0559632B1 (enExample)
JP (1) JP3333846B2 (enExample)
AT (1) ATE169957T1 (enExample)
CA (1) CA2090650C (enExample)
DE (1) DE69320389T2 (enExample)
DK (1) DK0559632T3 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
GB9215541D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (de) * 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
DK0837883T3 (da) * 1995-06-07 2005-12-19 Chiron Corp Fremgangsmåde til oplösning, oprensning og genfoldning af protein
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
AU781717B2 (en) * 1998-04-24 2005-06-09 Csl Behring Gmbh Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
US6794159B1 (en) 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
AU2002365131B2 (en) * 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
AU2003243394B2 (en) 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7851433B2 (en) * 2003-08-13 2010-12-14 Novartis Vaccines And Diagnostics, Inc. Method of purifying TFPI and TFPI analogs
US20080286279A1 (en) * 2004-03-17 2008-11-20 Chiron Corporation Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
BRPI0611710A2 (pt) * 2005-06-24 2011-12-20 Drugrecure Aps administração às vias aéreas de inibidor do passo de fator tissular, em condições inflamatórias que afetam o trato respiratório
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
JP2010536870A (ja) * 2007-08-21 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
KR101179171B1 (ko) 2008-08-14 2012-09-03 주식회사 운화 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
SI2521568T1 (sl) * 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)

Also Published As

Publication number Publication date
DE69320389D1 (de) 1998-09-24
CA2090650C (en) 2008-01-29
CA2090650A1 (en) 1993-09-03
EP0559632A3 (enExample) 1995-03-29
JP3333846B2 (ja) 2002-10-15
JPH07274968A (ja) 1995-10-24
EP0559632B1 (en) 1998-08-19
DE69320389T2 (de) 1999-03-11
ATE169957T1 (de) 1998-09-15
EP0559632A2 (en) 1993-09-08
US5212091A (en) 1993-05-18

Similar Documents

Publication Publication Date Title
DK0559632T3 (da) Fremgangsmåde til fremstilling af vævsfaktorreaktionsvejsinhibitor
KR960703433A (ko) 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
HK8694A (en) Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
MY103892A (en) Interleukin-2 of high purity production and use
AU5191186A (en) Method for the purification of erythroppietin and erythropoietin compositions
DE69030582D1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
EP0132732A3 (en) Homologues from aprotinine whose lys 15 amino acid is substituted by other amino acids, process for their preparation and their use as medicaments
FR2562539B1 (fr) Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
EP0134385A3 (en) A protein having cell growth stimulating action, composition thereof and method for producing the same
IT1232670B (it) Procedimento per la purificazione delle acque reflue prodotte dagli impianti di produzione dell'urea.
DE3485488D1 (de) Imidazoliumsalze, zwischenprodukte fuer ihre herstellung sowie ihre verwendung.
IT1219874B (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
FI931332A0 (fi) Uusia alkyleenidiammoniumdiklavulanaattijohdannaisia, menetelmä niidenvalmistamiseksi samoin kuin niiden käyttö kalvulaanihapon puhdistamiseksi
BR8803293A (pt) Amidas de acido 6,7-dihidro-pirazolo(1,5-a arroba(1,3,5 arroba triazin-2-sulfonico,processo para sua preparacao,composicao herbicida e reguladora do crescimento de plantas,aplicacao e processo para preparacao da composicao
DK134889D0 (da) Overfladeaktive forbindelser og fremgangsmaade til fremstilling deraf
ES2093031T3 (es) Metodo para purificar el factor de crecimiento transformante (tgf).
DK102892A (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
AU604418B2 (en) Cosmetic composition
EP0373540A3 (en) Method for purifying fibroblast growth factor protein
EP0282363A3 (en) Method for preparation of a concentrate of alpha-1-antitrypsin from a human plasma fraction, and its use as a pharmaceutical
IL78455A0 (en) Method for purifying interferon and composition of matter produced thereby
IT1222427B (it) Procedimento per la purificazione di interferone
DE68928634D1 (de) Verfahren zur Herstellung von aktivierten Killer-Monozyten und Verfahren zur Überprüfung ihrer tumoriziden Aktivität
EP0241136A3 (en) Human class 1 heparin-binding growth factor
ES539669A0 (es) Un procedimiento para preparar acidos dicarboxilicos sulfu- rados y con un triple enlace